Filamentous aggregates (fibrils) are regarded as the final stage in the assembly of amyloidogenic proteins and are formed in many neurodegenerative diseases. Accumulation of aggregates occurs as a result of an imbalance between their formation and removal. Although there have been numerous studies of the aggregation process in vitro, far fewer studies of aggregate disassembly and degradation are available. Here we use single-aggregate imaging to show that large fibrils assembled from full-length tau are substrates of the 26S proteasome holoenzyme, which fragments them into small aggregates. TEM further revealed that these small aggregate species had no distinct structure. The intact proteasome holoenzyme is required to effectively target fibrils. Interestingly, while degradation of monomeric tau was not inhibited by ATPγS, fibril fragmentation was predominantly dependent on the ATPase activity of the proteasome. The proteasome holoenzyme was also found to target fibrils assembled from α -synuclein (αS), suggesting that its fibril fragmenting function may be a general mechanism. The fragmented species produced by the proteasome showed significant toxicity to human cell lines compared to intact fibrils. Together, our results indicate that the proteasome holoenzyme possesses a novel fragmentation function that disassembles large fibrils into smaller and more cytotoxic species. (196 words)
Introduction
Protein aggregation is often associated with neurodegenerative disorders and agingrelated dementia [1] . Alzheimer's and Parkinson's diseases are common dementia-like disorders involving the aggregation of distinct amyloidogenic proteins tau and α synuclein (αS), respectively [2, 3] . The protein tau is suggested to participate in the assembly and stability of microtubules but has also been associated with other functions [4] . α S is able to interact with phospholipids and vesicles and believed to be involved in cellular vesicle trafficking and neurotransmitter release [5] . Both tau and α S are largely intrinsically disordered when not associated with other proteins [6, 7] .
Amyloidogenic proteins have a propensity to misfold and oligomerize [8] . As oligomers grow in size by addition of protein monomers, conformational changes that are associated with increased stability take place, eventually resulting in a highly ordered and filamentous arrangement of aggregates that are no longer soluble in the physiological environment [9] . How these aggregates relate to toxicity leading to cell death and ultimately cause pathological disorders remain disputed, though distinct types of aggregates have been found to impede cellular signaling and compromise the integrity of neuronal functions [10] [11] [12] [13] . The size and the type of aggregates may also determine how they are processed by cells and either targeted for degradation or sequestered at distinct cellular sites (e.g. [14] ).
Although the formation of aggregates has been researched extensively, little is known about their removal. Aggregate degradation via both the proteasomal and the lysosomal systems has been described in the literature (e.g. [15, 16] ). Whereas larger aggregates are believed to be cleared by lysosomes, removal of smaller oligomers has been attributed to the proteasome [17] . The 26S proteasome holoenzyme is an abundant multisubunit protein complex responsible for the regulation of many key signaling pathways and general cell homeostasis [18] . This complex consists of a cylindrically shaped 20S core particle (CP) and one or two 19S regulatory particles (RP) that cap the CP at either end [19] (Modeled in SFigure 1a). Degradation activity is provided by several proteases within the interior of the CP, while the RP is responsible for the recognition of ubiquitin(Ub)-modified substrates, which are subsequently unfolded and translocated into the CP [20] . Six ATPases arranged in a hexameric ring are found within the base of the RP, which couples ATP hydrolysis to substrate unfolding and translocation through its channel pore. In cells, both tau and α S have been reported to be degraded by the proteasome [21, 22] , while aggregates assembled from these proteins were not found to be targeted by the proteasome in vitro (e.g. [23, 24] ). It is further possible that distinct aggregate conformations of sufficient size and stability may be recognized but not processed by the proteasome and thus inhibit its activity, as has been suggested for tau, α S, amyloid-β and prion aggregates [23, [25] [26] [27] .
Here we use single-aggregate total internal reflection fluorescence (TIRF) microscopy to show a novel aggregate fragmentation function of the proteasome holoenzyme, which targets fibrils in a Ub-independent manner. Fibrils assembled from full-length tau were predominantly removed by the proteasome in an ATP-dependent manner, while inhibiting the proteolytic activity of the proteasome had negligible effect on the fragmentation function. Fragmentation was further confirmed by transmission electron microscopy (TEM), revealing a species that resembled amorphous aggregates following proteasome treatment. This aggregate species was more toxic to cultured mammalian cells than fibrils, triggering a significant level of cell death. Our findings were further confirmed using α S fibrils, suggesting that this fragmenting function is not restricted to targeting tau fibrils. Together our findings demonstrate a novel ability of the proteasome holoenzyme to disassemble fibrils and its activity may be regulated through altering the physiological ratio of the holoenzyme to the free proteasomal core and regulatory particles.
Results

Proteasome holoenzyme degrades monomeric tau
To study how filamentous aggregates (fibrils) may be processed by mammalian proteasomes (SFigure 1a), we purified the holoenzyme or the RP separately from established HEK293T cells [28] This result suggests that the degradation of monomeric tau is dependent on the proteolytic but not the ATPase-catalysed unfolding-translocation activity of the proteasome and that Velcade is sufficient to fully inhibit proteasomal degradation of tau proteins.
Tau fibrils are fragmented in presence of the proteasome holoenzyme
We next tested whether aggregates assembled from tau may also be targeted by the proteasome holoenzyme. Fibrils assembled from tau could be reproducibly obtained at similar levels after 24 hrs of aggregation reaction following established protocols (e.g. [30] ). Aggregated tau samples were treated with the proteasome or an ATPcontaining buffer control and subsequently mixed with a second solution containing pentameric formylthiophene acetic acid (pFTAA, Figure 1a ), a fluorophore that emits fluorescence upon binding to amyloid structures in aggregates [31] . We further established an approach to detect aggregated proteins directly on a glass coverslip surface (Figure 1b, left) . Our approach does not require prior labeling of tau proteins and permits fluorophores in solution to reversibly bind the aggregates, thereby prolonging imaging lifetime. Aggregates were imaged on a custom-built fluorescence TIRF microscope (SFigure 3a) and analyzed using custom-written scripts that we have developed to assess individual aggregate size and fluorescence intensity, which in turn reflects the level of amyloid structures present (SFigure 3b and Materials and Methods).
The size (apparent length) of individual pFTAA-positive aggregates as detected by TIRF was plotted against their fluorescence intensity and presented in two-dimensional (2D) graphs. The level of amyloid structures defined in each aggregate increases proportionally with aggregate size (SFigure 3c). Based on the contours of aggregates, we will refer to the large aggregates (length >1 µm) with distinct shapes and high amyloid structure content as fibrils and those with indistinct morphology due to the diffraction limit (length < 1 µm) as small aggregates (Figure   1b right and SFigure 3d).
Large fibrils (up to 15 µm in length) assembled from tau proteins could still be detected even after 20 hrs of incubation in the degradation buffer without the proteasome. These fibrils constituted about 55% of all aggregates (510 fibril and 419 small aggregate counts, Figure 1c ). In comparison, incubation with the proteasome holoenzyme quantitatively removed tau fibrils (95 counts, 7% of total), while the level of small aggregates increased (562 counts, Figure 1d ). The standard deviation from the mean of experiments was less than 20% for both fibrils and small aggregates.
Proteasomes alone did not bind pFTAA and therefore could not contribute to any fluorescence signals detected (SFigure 4a). An ATP regeneration system was added to both the control and proteasome-treated samples to maintain the ATP concentration during the assay (see Materials and Methods).
Fibrils are targeted by ATP-dependent proteasomal activity
An equilibrium may potentially exist between fibrils, soluble oligomers and monomers, the last of which could be degraded by the proteasome and thus lead to an equilibrium shift favoring fibril disassembly. To validate that fibrils were being targeted by the proteasome, we repeated the experiments in Figure 1c incubation with the holoenzyme led to fibril fragmentation, resulting in a drop in the level of fibrils (155 counts, 12% of total) and an increase in the number of small aggregates (891 counts, Figure 2b) . These results indicate the presence of a novel proteasomal function that fragments tau fibrils. Plausibly, the proteasome may fragment a single fibril into many small aggregates, at least some of which may be detected by TIRF imaging. The increase in the level of small aggregates here is in agreement with Figure 1 and suggests that fibrils may have been fragmented into smaller species of no more than 1 µm in size. We further addressed the possibility of contamination by canonical chaperones that may be responsible for fibril fragmentation; the fragmenting activity was unaffected by inhibitors of HSP70, HSP90 or VCP/p97 (SFigure 4b-e). Therefore, the loss of fibrils and the increase in small aggregates appear to be results of proteasomal action.
To gain insights into the proteasomal mechanisms responsible for this fibrilfragmenting function, we repeated the same assay using holoenzymes pre-treated with either Velcade or ATPγS. Fragmentation was largely observed (83 counts of remaining fibrils) even after inhibition of proteolytic activity (proteasome Velcade , Figure 2d ), further excluding the scenario that proteolytic degradation of tau proteins mediates the loss of fibrils. The number of small aggregates (290 counts) remained at a similar level as control in Figure 2a . In contrast, compromising the ATP-dependent activity (proteasome ATPγS ) impeded the fragmenting function, leaving the fibril level largely unchanged (660 counts, Figure 2e ). The lower ratio of fibrils (30%) when incubated with proteasome ATPγS is due to the apparent level of small aggregates detected (1341 counts). These observations together imply that the fragmentation of fibrils relies predominantly on the ATPase activity the proteasome.
Integrity of proteasome holoenzyme required for fibril fragmentation
Since fibril fragmentation was mainly dependent on proteasomal ATPase activity, we attempted to independently verify our observations using purified free RPs.
Unexpectedly, no significant fibril fragmentation was detected in the presence of RP (Figure 2e) , and the level of fibrils (619 counts, or 40% of total) remained largely similar to Figure 2a . This result suggests that the integrity of the proteasome holoenzyme may be required to couple functions that are required for efficient fibril fragmentation.
Distinct activities of proteasome holoenzyme prevent tau aggregation
While the fibril-fragmenting function of proteasome holoenzymes may be relevant to target aggregates that are already assembled, e.g. in a scenario when aggregates enter the host cell from the extracellular environment (e.g. [32] [33] [34] ), the proteasomal mechanisms that are involved in clearing cytosolic misfolded proteins to prevent intracellular aggregate formation may be distinct from its fibril-fragmenting function.
To further validate the observations in Figure 2 and mimic a physiological scenario where proteasomes are already present during the aggregation process, we attempted to assemble tau aggregates in the presence the holoenzyme. Without the proteasome, fibrils emerged 0.5 hr after aggregation start (Figure 3a) , and a significant number of fibrils (994 counts or 34% of total, Figure 3b ) was observed after 24 hrs of reaction.
In comparison, aggregation in the presence of holoenzymes restricted the ratio of fibrils (13%, 141 counts) assembled after 24 hrs (Figure 3c) . Selectively inhibiting the proteolytic or ATPase activities of the proteasome partly restored the fibril level (704 and 978 counts, respectively, Figure 3d and e), suggesting that both activities are involved in impeding fibril formation from protein monomers. It therefore appears that the proteasomal mechanisms observed here, which are involved in reducing tau aggregation, are distinct from the fibril-fragmenting function in Figure 2 , where the proteasomes were introduced to pre-assembled fibrils. Interestingly, proteasome ATPγS incubation enabled both more and large fibrils (over 10 µm) to form compared to proteasome Velcade , consistent with a central role of the ATPase activity in fibril disassembly.
TEM detects amorphous structures following proteasome treatment
The fragmentation function of the proteasome in Figure 2 was further independently validated using TEM. Fibrils in the absence of the proteasome remained intact after incubation with buffer control (Figure 4a) . These fibrils were lost following proteasome treatment, and only unstructured clusters of proteins resembling amorphous aggregates were detected (Figure 4b) , which were not present without proteasome treatment. Due to the intrinsic properties of uranyl acetate, which stains aggregates as well as proteasomes, we repeated these experiments using immunogold labeling with an anti-tau antibody to confirm the presence of tau proteins within these amorphous structures. This approach selectively labeled fibrils in the control sample (Figure 4c) , as well as the fragmented species of amorphous structures after proteasome treatment (Figure 4d) . These data indicate that tau-containing amorphous structures are formed following fibril fragmentation by the proteasome. Because the dimensions of these amorphous aggregates are mostly less than 1 µm, they are likely to have contributed to the small aggregates observed in Figure 2 .
Intact proteasome holoenzymes could be detected under TEM after overnight incubation with the sample (see Figure 4b ). This suggested that aggregated tau proteins did not affect the integrity of the holoenzyme. Consistently, we detected no quantitative inhibition of the proteasomal peptidase activity against a model substrate LLVY-AMC in the presence of fibrils or by a heparin-containing aggregation buffer (SFigure 5a), and incubating fibrils with the active proteasome holoenzyme for 20 hrs did not affect its ability to hydrolyze ATP (SFigure 5b). Although it may be possible that other proteasomal functions such as Ub-dependent degradation may be impaired as a result of prolonged interaction with aggregated tau proteins, any such inhibitory effect would not affect interpretation of our fragmentation data.
Fibril fragmentation may increase cell lysis
Aggregates assembled from amyloidogenic proteins have been suggested to trigger cell stress and cytotoxicity, for example by disrupting lipid bilayers [35] . We hypothesized that the fibril-fragmenting function of the proteasome holoenzyme that resulted in a higher number of small aggregates would also lead to increased cytotoxicity, manifested through cell death (referred to as 'cytotoxicity' hereafter). To assess the cytotoxicity associated with fibril fragmentation, we incubated mammalian cells with untreated fibril samples or fragmented species and measured cell viability Since the total number of aggregates increases after proteasome treatment, we addressed whether a higher concentration of fibrils would also lead to increased cell lysis. Cells incubated with fibrils alone at one-, ten-or hundred-fold higher concentration than in To test whether the fibril-fragmenting function may also be promiscuous and target other amyloidogenic proteins, we assembled fibrils from recombinant wild-type α S following previously established protocols (e.g. [36] ). Purified monomeric α S is a substrate of the proteasome holoenzyme, and like tau its degradation is also dependent on the proteolytic but not the ATPase activity of the holoenzyme (SFigure 7). Fibrils assembled from α S could be reproducibly detected (1413 counts, or 28% of total)
under the TIRF microscope after 20 hrs of incubation with buffer control (Figure 6a) .
These fibrils were fragmented by the proteasome holoenzyme, resulting in a decrease in the number of fibrils (1081 counts or 9%, Figure 6b ). The lower ratio of fibrils is due to a substantial increase in the number of small aggregates (from 3682 to 10864 counts) following proteasome treatment. When untreated or proteasome-treated fibrils were stained with uranyl acetate and imaged by TEM, we detected smaller aggregate species of distinct structures following fragmentation (Figure 6c and d) . These species were not amorphous and may account for the higher fluorescence signal detected by TIRF imaging after fragmentation of α S fibrils. Similarly to tau, fragmented α S entities were also significantly more toxic to cells (~28% cell lysis) than intact fibrils (~3% lysis, Figure 6e ). Overall, the conservation of the fragmenting function against both tau and α S fibrils suggests that the proteasome holoenzyme may serve as a promiscuous fibril fragmentase and able to indiscriminately target fibril structures in general.
Discussion
We have identified in this study a novel fibril-fragmenting function of the proteasome holoenzyme, which targets fibrils assembled from tau and α S proteins in an ATPdependent manner and does not require its proteolytic activity. This novel fibriltargeting function makes the proteasome holoenzyme a structurally and functionally distinct fibril-fragmenting enzyme compared to other aggregate-targeting enzymes in the existing family of disaggregases such as Hsp104, which reverses aggregation of prion proteins [37] ; and several HSP70-containing disaggregase complexes [38, 39] , one of which reported to target α S aggregates [39] . We further showed that this fragmenting function of the proteasome on pre-assembled fibrils is distinct to the proteasomal actions involved in preventing aggregation of misfolded proteins, which requires both the ATPase and proteolytic activities.
The proteasome has canonically been described to target oligomers and smaller aggregates in solution, whilst degradation of larger filamentous aggregates is performed by the lysosomal system [17] . We provide evidence in this study that amend this view, showing a novel ability of proteasome holoenzymes with molecular dimensions ~15 × 40 nm (pdb-id: 5GJR) to fragment fibrils up to ~20 µm in length independently of Ub modification. The recent molecular structure of tau filaments derived from an Alzheimer's patient reveals extensive β -sheet stacking of tau monomers, suggesting a high degree of stability [40] . Our results therefore imply a remarkable ability of the proteasome to target and fragment stable structures several orders of magnitude larger.
Early in vitro studies have suggested an ATP-dependent chaperone-like function of the RP with affinity to denatured protein structures without Ub modification [41] . Recent in vivo studies have further found proteasomal recruitment to aggresomes in HEK cells [42, 43] and to poly-GA aggregates in neurons [44] , hinting a plausible proteasome involvement in targeting aggregates. Our findings in this study provide additional evidence suggesting that the ATP-dependent fibril-fragmenting function may also be driven by the unfolding or chaperone-like mechanism, perhaps when substrates cannot be a proteolytic target susceptible to direct degradation.
The current study has focused on the fibril-fragmenting function of proteasome holoenzymes on unmodified recombinant tau and α S. Under physiological settings, extensive posttranslational modifications have been identified on tau that affect its aggregation properties or are associated with pathological consequences [45, 46] . Similar effects of various posttranslational modifications have also been reported for α S [47] [48] [49] . The range of aggregate species found in vivo that may be targeted by the fibril-fragmenting function of the proteasome, or alternatively those that are resistant to or inhibitory of this function, remain to be studied.
Identification of the proteasome holoenzyme with a novel fibril fragmenting activity, in addition to its canonical role as a mediator of the degradation of misfolded proteins, could be an interesting amendment to the repertoire of cellular instruments targeting protein aggregation.
Materials and Methods
Protein purification
Plasmids expressing untagged full-length tau (isoform 0N4R) containing a single Purification of mammalian proteasome holoenzymes or the free regulatory particle (RP) was carried out as described elsewhere [28] . Briefly, mammalian 
Image analysis
Individual image data were averaged over all the frames by the average intensity projection at z-axis using ImageJ (National Institute of Health, USA) and then subjected to image processing. A custom-written MATLAB script (MathWorks) was used to analyze the averaged images. Individual images were first top-hat and bpass filtered to remove the camera noise and partitioned into a foreground and a background. To identify particles, the foreground was blurred using a 2D Gaussian filter with a threshold applied based on the original pixel intensity with a criterion of 2% intensity above the background, and then established boundaries for individual particles. The particle length was measured by thinning boundaries of individual particles and thus calculated with an image pixel size of 235 nm for our TIRF setup.
To eliminate the background effect in intensity calculation, signal-to-background ratio (SBR) was introduced to correct pixel intensity, where each pixel's SBR is defined as:
For a given particle, its corrected intensity is the sum of each pixel's SBR values within its boundary.
TEM imaging
Samples for TEM imaging were prepared as for TIRF imaging and applied onto a carbon-coated 400 mesh copper grid (Agar Scientific). Proteasome samples were applied at 100 nM final concentration. Samples were stained with 2% (w/v) uranyl SBR = Intensity above the background Background acetate for 1 min and subsequently washed twice with ddH 2 O. TEM images were acquired using Tecnai G2 microscope (13218, EDAX, AMETEK) operating at an excitation voltage of 200 kV.
Cytotoxicity assays
Fibrils treated with either the Proteasome buffer or with the proteasome holoenzyme (described in the Proteasome Assays section) were added in triplicate to confluent HEK293A cells grown in 96-well plates. The cells were subsequently incubated at 37 °C for 24 hrs in 200 µl final media volume, from which 100 µl was removed for LDH assay (Thermo Fisher). We followed manufacturer's protocols and added 100 µl of the supplied Reaction Mixture, which contains the substrates for LDH activity detection, to the media. After 30 min, the reactions were quenched with the Stop Buffer (supplied with the kit) and the absorbance at 480 nm was measured on a plate reader. Lysis media supplied by the manufacturer was then added to each well to establish the maximum level of cell lysis. Assays were repeated at least three times using a new protein preparation each time. Both Velcade and ATPγS alone were found to be toxic to cells when added to the cells at the concentration used for proteasome inhibition, as significant levels of cell lysis was observed. 
